文献速递免疫规划传染病防控与疫情报告

含或不含MF59®佐剂的递增剂量甲型H7N9流感灭活疫苗的安全性与免疫原性

Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.
PubMed 文献 · Vaccine · 2025-01-10

一项II期研究在18-64岁健康成人中评估两剂2017年大流行前甲型H7N9灭活疫苗(间隔21天肌内接种)的安全性和免疫原性。受试者随机接受3.75 μg、7.5 μg或15 μg血凝素(HA)加MF59®佐剂(每组n=105),或15 μg HA无佐剂疫苗(n=57)。三种佐剂疫苗和15 μg无佐剂疫苗均安全且耐受良好;佐剂剂量平均提供比15 μg无佐剂疫苗更高的抗体反应,但所有组达到血清转化和抗体滴度≥40的比例仍低于50%。

要点

  • 三种MF59佐剂疫苗和15 μg无佐剂疫苗均安全且耐受良好。
  • 二次接种后佐剂组血凝抑制(HAI)、中和(Neut)和神经氨酸酶抑制(NAI)几何平均滴度升高,在二次接种后21天达峰。
  • 所有组HAI滴度≥1:40比例和血清转化率仍低于50%。

核心结论

  • 佐剂疫苗剂量平均提供比15 μg无佐剂疫苗更高的抗体反应。
  • 所有研究组达到血清转化和抗体滴度≥40的受试者比例仍低于50%。

研究设计与样本

  • 在18-64岁健康成人中开展II期研究,评估两剂2017年大流行前甲型H7N9灭活疫苗间隔21天肌内接种的安全性和免疫原性。
  • 受试者随机分配至第1-3组(每组n=105)分别接受3.75 μg、7.5 μg或15 μg血凝素(HA)加MF59®佐剂,或第4组(n=57)接受15 μg HA无佐剂疫苗。

主要发现

  • 三种MF59佐剂疫苗和15 μg无佐剂疫苗均安全且耐受良好。
  • 首次接种后各研究组 terhadap A(H7N9)疫苗抗原的抗体活性检测很少。
  • 二次接种后,三个佐剂组血凝抑制(HAI)、中和(Neut)和神经氨酸酶抑制(NAI)几何平均滴度(GMT)升高,在二次接种后21天达峰。
  • 佐剂组和无佐剂组HAI滴度≥1:40的受试者百分比分别为30-43%和0,血清转化率分别为0和0。
  • 针对抗原漂移的A(H7N9)毒株A/Shanghai/2/2013和A/Guangdong/17SF003/2016的抗体反应呈现相似趋势。

局限性

  • 所有研究组达到血清转化和抗体滴度≥40的受试者比例仍低于50%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat. METHODS: A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.75 μg, 7.5 μg or 15 μg of hemagglutinin (HA) with MF59® adjuvant, or 15 μg of HA unadjuvanted vaccine (n = 57, Arm 4). RESULTS: The three MF59 adjuvanted vaccines and the 15 μg unadjuvanted vaccine were safe and well-tolerated. Little antibody activity was detected against the A(H7N9) vaccine antigen after the first vaccination across study Arms. After second vaccination, the three adjuvanted Arms showed increases in hemagglutination inhibition (HAI), neutralizing (Neut), and neuraminidase inhibition (NAI) geometric mean titers (GMT), peaking at 21 days post second vaccination. The percentage of participants with titer ≥1:40 and seroconversion rates for HAI were 30-43 % and 0 for the adjuvanted Arms and the unadjuvanted Arm, respectively. Antibody responses against antigenically drifted A(H7N9) strains A/Shanghai/2/2013 and A/Guangdong/17SF003/2016 showed similar trends. Exploratory linear modeling of HAI and Neut responses post second vaccination revealed significantly lower log antibody titers among older participants (aged 35-49 and 50-64 years) compared to participants aged 18-34 years after adjusting for study vaccination, BMI, sex, and prior seasonal influenza vaccination. Post second vaccination, participants who received seasonal influenza vaccination in at least one of the two previous seasons had significantly lower log antibody titers than participants who did not. CONCLUSION: Adjuvanted doses of vaccine provided higher antibody responses, on average, than the 15 μg unadjuvanted vaccine. Proportion of participants achieving seroconversion and antibody titers ≥40 remained below 50 % in all study Arm.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Frey SE, Brady R, Jackson L, et al. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®. Vaccine. 2025. PMID: 39798434. doi:10.1016/j.vaccine.2024.126702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。